The BRICS TimesThe medicine marks the nation’s first homegrown EZH2 inhibitor
Jiangsu Hengrui Pharmaceuticals announced on Monday that the National Medical Products Administration has granted conditional authorization for its latest oncology treatment, Zeprumetostat.
The newly approved drug is intended for adult patients diagnosed with relapsed or refractory peripheral T-cell lymphoma, a rare and aggressive form of blood cancer, who have already undergone at least one systemic therapy. This particular type of lymphoma has historically had very limited treatment avenues, making new therapeutic options vital.
Zeprumetostat represents China’s first domestically developed EZH2 inhibitor. EZH2, an enzyme linked to the growth of cancer cells, has become a major target in the development of modern oncology drugs. According to Hengrui, the therapy is designed as a selective oral medication, with the goal of bringing fresh hope to patients facing this difficult illness.
The announcement led to a rise in Hengrui’s stock, which increased by 0.6 percent to reach 68.76 yuan ($9.63) during the midday trading session on the Shanghai Stock Exchange.
Because the approval was granted conditionally, the company can begin marketing the drug while continuing to provide additional long-term clinical evidence regarding its safety profile and overall efficacy.
